Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 133
3 154
2 51
1 25
NEB 4
Curative setting
A 54
C 2
NEB 4
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 37
Endocrine Tumours 21
Gastrointestinal Cancers 73
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 12
Skin Cancers 29
Thoracic Malignancies 85
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 11
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Nivolumab - Ipilimumab Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older* CheckMate 067
    Skin Cancers
    		 Cutaneous Melanoma - CheckMate 067

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Ipilimumab - Glycoprotein 100 (GP100) Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era) MDX010-20
    Skin Cancers
    		 Cutaneous Melanoma HLA-A*0201 MDX010-20

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Vemurafenib - Dacarbazine As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma BRIM-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E BRIM-3

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Vemurafenib - Dacarbazine As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma BRIM-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600K BRIM-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Trametinib - Dacarbazine or paclitaxel As monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation METRIC
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 METRIC

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Dabrafenib + trametinib - Dabrafenib Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation COMBI-d
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COMBI-d

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Dabrafenib - Dacarbazine Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation BREAK-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E BREAK-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Dab/Tram (dabrafenib and trametinib) - Vemurafenib Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation COMBI-v
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COMBI-v

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Cobimetinib Vemurafenib Vemurafenib + placebo In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation coBRIM
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E coBRIM

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A
    Nivolumab - Dacarbazine As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults CheckMate 066
    Skin Cancers
    		 Cutaneous Melanoma - CheckMate 066

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Ipilimumab Dacarbazine Dacarbazine + placebo Advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (Basis of EMA and FDA approval of 1st-line ipilimumab monotherapy) CA184-024
    Skin Cancers
    		 Cutaneous Melanoma - CA184-024

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Pembrolizumab - Investigator-choice chemotherapy (Randomised phase II study) Adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma KEYNOTE-002
    Skin Cancers
    		 Cutaneous Melanoma - KEYNOTE-002

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pembrolizumab - Investigator-choice chemotherapy (Randomised phase II study) Adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma KEYNOTE-002
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 KEYNOTE-002

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Everolimus - Placebo Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease RADIANT 4
    Endocrine Tumours
    		 Neuroendocrine Tumour - Gastrointestinal or lung - RADIANT 4

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Cabozantinib - Placebo Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma EXAM
    Endocrine Tumours
    		 Thyroid Cancer - medullary TKI targeting RET, MET, VEGFR2 EXAM

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Dinutuximab Cis retinoic acid+GMCSF+IL2 Cis retinoic acid <32 years old with high-risk neuroblastoma after remission and stem cell transplatation
    Brain Tumours
    		 Neuroblastoma - -

    A

    PRELIMINARY SCORE

    • DFS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Radium-223 Best standard of care Best standard of care + placebo Treatment of adult patients with mCRPC, symptomatic bone metastases and no known visceral metastases, in progression after ≥2 prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment ALSYMPCA
    Genitourinary Cancers
    		 Prostate cancer - ALSYMPCA

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Abiraterone Prednisone Prednisone + placebo Indicated with prednisone or prednisolone for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based ChT regimen COU-AA-301
    Genitourinary Cancers
    		 Prostate cancer - COU-AA-301

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Enzalutamide - Placebo Adult men with mCRPC whose disease has progressed on or after docetaxel therapy AFFIRM
    Genitourinary Cancers
    		 Prostate cancer - AFFIRM

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Enzalutamide - Placebo Castraction-refractory pre-docetaxel (early termination with crossover) PREVAIL
    Genitourinary Cancers
    		 Prostate cancer - PREVAIL

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Docetaxel Q3w Prednisone or prednisolone Mitoxantrone ± prednisone or prednisolone In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer TAX 327 study
    Genitourinary Cancers
    		 Prostate cancer - TAX 327 study

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Cabazitaxel Prednisone or prednisolone Mitoxantrone ± prednisone or prednisolone In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen TROPIC
    Genitourinary Cancers
    		 Prostate cancer - TROPIC

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Nivolumab - Everolimus As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults CheckMate025
    Genitourinary Cancers
    		 Renal cell cancer - CheckMate025

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Axitinib - Sorafenib Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or cytokine AXIS
    Genitourinary Cancers
    		 Renal cell cancer - AXIS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Sunitinib First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease COMPARZ
    Genitourinary Cancers
    		 Renal cell cancer - COMPARZ

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Sunitinib - Interferon Treatment of advanced/metastatic renal cell carcinoma in adults
    Genitourinary Cancers
    		 Renal cell cancer - -

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Sorafenib - Placebo Patients with advanced RCC who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy TARGET
    Genitourinary Cancers
    		 Renal cell cancer - TARGET

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Everolimus - Placebo (Crossover allowed) Patients with advanced RCC, whose disease has progressed on or after treatment with VEGF-targeted therapy RECORD-1
    Genitourinary Cancers
    		 Renal cell cancer - RECORD-1

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Pazopanib - Placebo (Crossover allowed) First-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease Study VEG105192
    Genitourinary Cancers
    		 Renal cell cancer - Study VEG105192

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Bevacizumab Interferon Interferon + placebo In combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer AVOREN
    Genitourinary Cancers
    		 Renal cell cancer - AVOREN

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.